First patient dosed in Phase 2 of I-Mab’s clinical trial of cancer medicine candidate

I-Mab, a clinical stage biopharmaceutical company in Gaithersburg committed to the discovery, development and commercialization of novel biologics, Thursday announced that the first patient has been dosed in a phase 2 clinical trial of TJ107 (efineptakin alpha), a novel long-acting recombinant human interleukin-7 (rhIL-7),  in patients with glioblastoma multiforme (GBM) in China. The phase 2 trial is a ...

To purchase a reprint of this article, contact reprints@thedailyrecord.com.